Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
Removal of bone marrow and evaluation of its histologic picture.
Progenitor cells from which all blood cells derive.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
Bone loss due to osteoclastic activity.
Tumors or cancer located in bone tissue or specific BONES.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.
Diseases of BONES.
Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Transplantation of an individual's own tissue from one site to another site.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.
An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The process of bone formation. Histogenesis of bone including ossification.
Extracellular substance of bone tissue consisting of COLLAGEN fibers, ground substance, and inorganic crystalline minerals and salts.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
The grafting of bone from a donor site to a recipient site.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
An encapsulated lymphatic organ through which venous blood filters.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone.
Elements of limited time intervals, contributing to particular results or situations.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Synthetic or natural materials for the replacement of bones or bone tissue. They include hard tissue replacement polymers, natural coral, hydroxyapatite, beta-tricalcium phosphate, and various other biomaterials. The bone substitutes as inert materials can be incorporated into surrounding tissue or gradually replaced by original tissue.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Neoplasms containing cyst-like formations or producing mucin or serum.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
The longest and largest bone of the skeleton, it is situated between the hip and the knee.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A general term for various neoplastic diseases of the lymphoid tissue.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Breaks in bones.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
Bone-growth regulatory factors that are members of the transforming growth factor-beta superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
The number of CELLS of a specific kind, usually measured per unit volume or area of sample.
A potent osteoinductive protein that plays a critical role in the differentiation of osteoprogenitor cells into OSTEOBLASTS.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Antibodies produced by a single clone of cells.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the SKIN.
Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.
An individual that contains cell populations derived from different zygotes.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. (1/285)

BACKGROUND: The purpose of this study was to elucidate the clinical reliability of immunoscintigraphy (IS) to detect infiltration of the bone marrow in patients with malignant lymphoma. PATIENTS AND METHODS: Whole body IS was performed in 103 patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) using Tc-99m labelled anti-NCA-95 which allows visualization of the granulopoietic bone marrow. Of these, 52% were studied prior to any therapy. Findings were compared to posterior iliac crest biopsy as well as MRI and/or follow-up examination. Criteria of marrow infiltration were a positive biopsy, positive follow-up, or positive results of MRI. RESULTS: Comparison of IS and biospy revealed concordant findings in 69 and discordant findings in 34 of 103 patients. Of the 34 patients with discordant results, IS showed lesions suspicious of bone marrow infiltration in 29 patients despite normal biopsy findings. When follow-up and additional examinations were taken into consideration, 10 patients remained with probably false positive and five with false negative IS findings. IS proved to be highly sensitive and specific in patients with HD (100% and 84%, respectively) and high-grade NHL (93% and 84%, respectively). Moderate sensitivity (60%) was found in low-grade NHL. This was possibly due to false negative IS in three to five patients with chemotherapy in contrast to one of five false negative results in patients without chemotherapy. CONCLUSION: Bone marrow scintigraphy using antigranulocyte antibodies is highly sensitive in HD and high-grade NHL. Positive findings in IS subsequent to a negative biopsy should be followed by guided re-biopsy or MRI.  (+info)

Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. (2/285)

BACKGROUND AND OBJECTIVE: The tracer tachnetium-99m-2-methoxy-isobutyl-isonitrile (Tc99m-sestaMIBI) has recently been shown to concentrate in some neoplastic tissues, including myeloma. We investigated the diagnostic capacity and limits of this procedure in tracing focal myeloma lesions, and compared them with those of conventional radiological procedures (Xr). DESIGN AND METHODS: We studied 55 patients suffering from multiple myeloma (MM) or solitary plasmacytoma in different stages and clinical conditions, or from monoclonal gammopathy of undefined significance (MGUS), by whole body scans obtained 10 minutes after injection of 555 MBq of Tc99m-sestaMIBI. Scans were defined as normal (physiological uptake only), diffuse (presence of bone marrow uptake), or focal (localized areas of uptake), and were compared to conventional skeletal Xr. RESULTS: Thirty patients showed no focal areas of Tc99m-sestaMIBI uptake; this group consisted of 5 patients with MGUS, 6 with MM in stage IA and 2 in stage IIA, 11 patients studied after effective chemotherapy and 6 in early relapse. Twenty-five patients showed one or more spots of focal uptake: all of them had active disease (untreated, resistant or relapsing MM). In the setting of tracing focal lesions, Tc99m-sestaMIBI scans were concordant with the radiological examination in 38 patients and discordant in 17. Among the latter, in 4 cases Tc99m-sestaMIBI revealed focal lesions not detected by Xr, and in 13 cases lytic areas detected by Xr did not show Tc99m-sestaMIBI uptake. INTERPRETATION AND CONCLUSIONS: In untreated patients, the number of lesions revealed by Tc99m-sestaMIBI was comparable to that shown by Xr, while in pretreated patients Tc99m-sestaMIBI traced a number of lesions lower than that detected by Xr. The reason for this discrepancy is that Tc99m-sestaMIBI traces only active lesions. Tc99m-sestaMIBI limitations in identifying focal lesions may derive from the dimension of the smallest traceable lesion (about one centimeter), and from the possibility that focal plasma cell localizations in collapsed bone may not be visualized due to inadequate vascularization. Tc99m-sestaMIBI scintigraphy is an interesting tool for diagnosing, staging and following up focal myeloma lesions, in the bone as well as in soft tissues. It is more specific than conventional Xr in identifying sites of active disease.  (+info)

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. (3/285)

We report on the efficacy and toxicity of a sequential high-dose therapy with peripheral blood stem cell (PBSC) support in 85 patients with high-risk stage II/III breast cancer. There were 71 patients with more than nine tumour-positive axillary lymph nodes. An induction therapy of two cycles of ifosfamide (total dose, 7.5 g m(-2)) and epirubicin (120 mg m(-2)) was given, and PBSC were harvested during G-CSF-supported leucocyte recovery following the second cycle. The PBSC-supported high-dose chemotherapy consisted of two cycles of ifosfamide (total dose, 12,000 mg m(-2)), carboplatin (900 mg m(-2)) and epirubicin (180 mg m(-2)). Patients were autografted with a median number of 3.7 x 10(6) CD34+ cells kg(-1) (range, 1.9-26.5 x 10(6)) resulting in haematological reconstitution within approximately 2 weeks following high-dose therapy. The toxicity was moderate in general, and there was no treatment-related toxic death. Twenty-one patients relapsed between 3 and 30 months following the last cycle of high-dose therapy (median, 11 months). The probability of disease-free and overall survival at 4 years were 60% and 83%, respectively. According to a multivariate analysis, patients with stage II disease had a significantly better probability of disease-free survival (74%) in comparison to patients with stage III disease (36%). The probability of disease-free survival was also significantly better for patients with oestrogen receptor-positive tumours (70%) compared to patients with receptor-negative ones (40%). Bone marrow samples collected from 52 patients after high-dose therapy were examined to evaluate the prognostic relevance of isolated tumour cells. The proportion of patients presenting with tumour cell-positive samples did not change in comparison to that observed before high-dose therapy (65% vs 71%), but a decrease in the incidence and concentration of tumour cells was observed over time after high-dose therapy. This finding was true for patients with relapse and for those in remission, which argues against a prognostic significance of isolated tumour cells in bone marrow. In conclusion, sequential high-dose chemotherapy with PBSC support can be safely administered to patients with high-risk stage II/III breast cancer. Further intensification of the therapy, including the addition of non-cross resistant drugs or immunological approaches such as the use of antibodies against HER-2/NEU, may be envisaged for patients with stage III disease and hormone receptor-negative tumours.  (+info)

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. (4/285)

The role of androgen receptor (AR) mutations in androgen-independent prostate cancer (PCa) was determined by examining AR transcripts and genes from a large series of bone marrow metastases. Mutations were found in 5 of 16 patients who received combined androgen blockade with the AR antagonist flutamide, and these mutant ARs were strongly stimulated by flutamide. In contrast, the single mutant AR found among 17 patients treated with androgen ablation monotherapy was not flutamide stimulated. Patients with flutamide-stimulated AR mutations responded to subsequent treatment with bicalutamide, an AR antagonist that blocks the mutant ARs. These findings demonstrate that AR mutations occur in response to strong selective pressure from flutamide treatment.  (+info)

Detection and clinical importance of micrometastatic disease. (5/285)

Metastatic relapse in patients with solid tumors is caused by systemic preoperative or perioperative dissemination of tumor cells. The presence of individual tumor cells in bone marrow and in peripheral blood can be detected by immunologic or molecular methods and is being regarded increasingly as a clinically relevant prognostic factor. Because the goal of adjuvant therapy is the eradication of occult micrometastatic tumor cells before metastatic disease becomes clinically evident, the early detection of micrometastases could identify the patients who are most (and least) likely to benefit from adjuvant therapy. In addition, more sensitive methods for detecting such cells should increase knowledge about the biologic mechanisms of metastasis and improve the diagnosis and treatment of micrometastatic disease. In contrast to solid metastatic tumors, micrometastatic tumor cells are appropriate targets for intravenously applied agents because macromolecules and immunocompetent effector cells should have access to the tumor cells. Because the majority of micrometastatic tumor cells may be nonproliferative (G0 phase), standard cytotoxic chemotherapies aimed at proliferating cells may be less effective, which might explain, in part, the failure of chemotherapy. Thus, adjuvant therapies that are aimed at dividing and quiescent cells, such as antibody-based therapies, are of considerable interest. From a literature search that used the databases MEDLINE(R), CANCERLIT(R), Biosis(R), Embase(R), and SciSearch(R), we discuss the current state of research on minimal residual cancer in patients with epithelial tumors and the diagnostic and clinical implications of these findings.  (+info)

Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates. (6/285)

AIM: The presence of malignant cells in the blood and bone marrow of patients with cancer at the time of surgery may be indicative of early relapse. In addition to their numbers, the phenotypes of the micrometastatic cells might be essential in determining whether overt metastases will develop. This study aimed to establish a sensitive method for the detection and characterisation of malignant cells present in bone marrow. METHODS: In spiking experiments, SKBR3 cells were mixed with mononuclear cells in known proportions to mimic bone marrow samples with micrometastatic cells. Tumour cells were extracted using SAM-M450 Dynabeads coupled to the MOC-31 anti-epithelial antibody, and were further analysed for amplification of erbB2 and int2 by fluorescent in situ hybridisation (FISH). erbB2 and int2 copy numbers were also determined in 15 primary breast cancers, and bone marrow samples from patients with amplification were analysed for micrometastatic cells by immunomagnetic enrichment and FISH. RESULTS: In model experiments, cells with amplification could be detected in bead selected fractions when ratios of tumour cells (SKBR3) to mononuclear cells were as low as 10:10(7). Among the tumour samples, eight showed increased copy numbers of erbB2 and/or int2, and three of these patients had detectable numbers of tumour cells in their bone marrow: 4000, 540, and 26 tumour cells/10(7) mononuclear cells, respectively. The patient with 540 tumour cells/10(7) mononuclear cells showed high level amplification of erbB2 and suffered from a particularly aggressive disease, whereas the patient with 4000 tumour cells/10(7) mononuclear cells had favourable disease progression. CONCLUSION: These results demonstrate the feasibility and advantage of combining immunomagnetic selection and FISH characterisation of cancer cells in bone marrow samples. It is possible that molecular characterisation of such cells could provide prognostically valuable information.  (+info)

Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. (7/285)

The presence of prostate cancer cells in the bone marrow (BM) of patients with clinically localized disease is associated with an increased chance of disease recurrence; however, not all patients develop recurrence. We therefore sought to determine the phenotype of individual micrometastatic cells as a potential method to better predict disease outcome. Immunostaining was performed on BM cells from 46 patients whose BM RNA fraction had been identified to contain prostate-specific antigen mRNA. The prevalence of micrometastatic cells among BM mononuclear cells was determined using an anticytokeratin antibody. Mib-1 antibody was used to determine the percentage of micrometastatic cells that were proliferating. Micrometastatic cells were found in 96% of patient samples, with a 30-fold variation in prevalence ranging from 0.1-3.26/10(5) BM cells. Prior androgen ablation was associated with a reduced prevalence of micrometastatic cells (P = 0.010). In 68% of patients, some micrometastatic cells were judged to be proliferating at proportions ranging from 1 of 11 (9%) to 4 of 4 (100%). Higher Gleason score of the primary tumor was associated with a higher proliferative proportion of micrometastatic cells (P = 0.038). We conclude that, in patients with clinically localized disease, there is wide variability in the prevalence of micrometastatic cells and the proportion which are proliferating. Long-term follow-up will determine whether the development of clinically obvious metastatic disease is related to higher prevalence of micrometastatic cells in the marrow or the proportion that are proliferating.  (+info)

Oral etoposide for refractory and relapsed neuroblastoma. (8/285)

PURPOSE: To describe the efficacy of oral etoposide against resistant stage 4 neuroblastoma. PATIENTS AND METHODS: Patients with refractory or recurrent stage 4 neuroblastoma were treated with etoposide 50 mg/m(2) taken orally each day, in two or three divided doses, for 21 consecutive days. Treatment could be repeated after a 1-week period. Extent-of-disease studies included imaging with 131-iodine-metaiodobenzylguanidine and extensive bone marrow (BM) sampling. RESULTS: Oral etoposide was used in 20 children between the ages of 2 and 11 years (median, 6 years). Prior treatment included high doses of alkylating agents and a median of 4.5 cycles of etoposide-containing chemotherapy, with cumulative etoposide doses of 1,800 mg/m(2) to 3,935 mg/m(2) (median, 2,300 mg/m(2)). Oral etoposide produced antineuroblastoma effects in four of four children with disease refractory to intensive induction treatment; sampling variability could account for resolution (n = 3) or reduction (n = 1) of BM involvement, but improvement in other markers also occurred. Antineuroblastoma effects were also evident in five of five children with asymptomatic relapses after a long chemotherapy-free interval: BM disease resolved and all other disease markers significantly improved in two patients, and disease markers improved or stabilized in three patients on treatment for more than 6 months. In these nine patients, extramedullary toxicity was absent, neutropenia did not occur, transfusional support was not needed, and preliminary data suggested little immunosuppression (phytohemagglutinin responses). Oral etoposide was ineffective in all (11 of 11) patients with rapidly growing tumor masses. CONCLUSION: Given the absence of toxicity to major organs, the minimal myelosuppression or immunosuppression, and the antineoplastic activity in patients with low tumor burdens after high-dose chemotherapy, limited use of low-dose oral etoposide should be considered for inclusion in postinduction consolidative treatment programs aimed at eradicating minimal residual disease.  (+info)

INNSBRUCK, Austria-The presence of bone marrow micrometastases in women newly diagnosed with breast cancer is a highly significant predictor of poor outcome, according to a pooled analysis of data fro
The primary goal of this study was to determine whether the known antibody-dependent cytotoxicity of Edrecolomab (18) could be monitored in advanced breast cancer patients by repeating immunocytochemical bone marrow aspiration before and after antibody infusion. We were able to demonstrate that typing for EpCAM expression of micrometastatic breast cancer cells defined these cells as suitable targets of Edrecolomab, which was originally thought to be a cytotoxic agent for colorectal cancer cells only. Because extrapolation from antigen patterns expressed by the primary tumor has been shown to be unreliable (23) , phenotyping of bone marrow micrometastases by double-labeling techniques thus may help enlarge the therapeutic spectrum of monoclonal antibody therapy. On the basis of our present data, we believe that antigen expression by micrometastatic cells may be a better predictor of response to antibody-based therapy than expression by the related primary tumor. Our pilot study provides data that ...
In 1998, our group first reported isolation of HER2-positive CTCs from the peripheral blood of breast cancer patients with organ-confined tumors by means of the patented combined buoyant density gradient and immunomagnetic separation technique (10, 11). Against the background that breast cancer patients with distant metastasis at diagnosis had disseminated HER2-overexpressing epithelial cells in the bone marrow (15), the hypothesis was generated that at the time of primary treatment CTCs expressing the HER2-oncogenic receptor might be intermediates for the metastasis process. This assumption is further supported by the association between bone marrow micrometastases and the occurrence of HER2-positive cells. To the best of our knowledge, this is the first study to investigate the clinical relevance of HER2-positive CTCs in the peripheral blood of nonmetastatic breast cancer patients.. In this study, HER2-positive CTCs were present in the peripheral blood of 17 of 35 (48.6%) primary breast cancer ...
On live TV Monday morning, Robin Roberts announced she has been diagnosed with a rare blood and bone marrow disease. INSIDE EDITION has the latest.
Bone marrow is the spongy tissue inside some of the bones, such as your hip and thigh bones. It contains immature cells called stem cells. The stem cells can develop into the different types of blood cells.
Bone marrow a href=http://www.wittyfeed.com/story/14094/these-weird-diseases-haunting-theinternet-are-actually-badphotoshop target=_blank rel=nofollowdisease/a is found to be a very rare illness...
The mainstay of chemotherapy for ESFT is currently vincristine, cyclophosphamide, and doxorubicin, alternating with ifosfamide and etoposide (44) . With these drugs and adequate local control of the primary tumor, many patients with localized ESFT (excepting those with pelvic primary tumors) can be cured. However, for patients with high-risk ESFT (which includes pelvic primary sites and metastatic disease at diagnosis), the prognosis is much worse, especially for tumors with spread to bone or bone marrow (3 , 45) . Attempts to improve outcome for high-risk ESFT using intensive induction therapy followed by myeloablative chemotherapy with stem cell rescue have achieved responses, but improvement in overall survival has been disappointing due to recurrent disease, especially in patients with bone and/or bone marrow metastases at diagnosis (3 , 45, 46, 47, 48) .. One possible approach to improve therapy for metastatic ESFT could be to use intensive (myeloablative) chemoradiotherapy to maximally ...
Luekocytosis literally means abnormal increase in the Leukocytes or the white blood cells. Luekocytosis can be affirmed by if the number of leukocytes that are circulating in the peripheral blood exceeds the Normal White Blood Cell Count of 10,000 white cells per microliter.. As production and release of white blood cells is expected in cases of fighting foreign microorganisms that attempt to invade the body. Luekocytosis can also be caused by disorders in the immune system and by bone marrow tumors.. An increase in the Granulocytes (white blood cells with large granules in their cytoplasm) is noticeable during pregnancy. This increase gets more exaggerated during the labor and the first postpartum week.. Infants and newborns normally have a high count of leukocytes. This high level is very noticeable with neutrophil which drops down within 2 weeks after birth.. Luekocytosis can also be a result of heavy exercises, severe physical or emotional stress, expose to sunlight or cold.. Luekocytosis ...
Subjects with adequate bone marrow (WBC ≥4,000/mm3, Platelet ≥100,000/mm3, Hemoglobin≥9.0g/dL, ANC≥1,500/mm3), renal (Creatinine≤1.5 mg/dl) and hepatic [aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)/ alkaline phosphatase (ALP)≤3 x ULN, Total bilirubin ≤2.0 mg/dL] function. No significant heart and lung disease.. ※ For subjects with a liver metastases, AST/ALT/ALP≤ 5 x ULN is allowed; and for subjects with bone marrow metastases, ALP≤ 5 x ULN is allowed. ...
Successful Treatment with Continuous High-Dose 5-Fluorouracil Infusion, Followed by Oral Capecitabine in a Patient with Advanced Gastric Cancer with Bone Marrow Metastasis and Microangiopathic Hemolytic ...
VA-ES-BJ is an epithelioid sarcoma cell line derived in 1991 from a bone marrow metastasis removed from an adult male with primary vertebral epithelioid carcinoma.
VA-ES-BJ is an epithelioid sarcoma cell line derived in 1991 from a bone marrow metastasis removed from an adult male with primary vertebral epithelioid carcinoma.
Many people enjoy long and healthy lives after being successfully treated for their blood cancer. Sometimes, however, the treatment can affect a persons health for months or even years after it has finished. Some side-effects may not be evident until years after treatment has ceased. These are called late effects. Some people who have been treated with chemotherapy or radiotherapy may be at a higher risk of developing other diseases such as myelodysplastic syndrome (a bone marrow disease) and other (secondary) cancers including leukaemia and melanoma (a type of skin cancer). These cancer treatments also have been shown to increase the risk of cardiac (heart) problems, gut problems, and other organs may be affected too.. Evidence suggests that radiotherapy to the chest at a younger age may increase the chances of developing lung cancer, breast cancer or heart problems later in life. While anthrocycline-containing chemotherapy regimens, may increase the risk of developing heart problems or ...
Life expectancy ³ 3 months• Adequate organ function:Adequate hematological function: neutrophil count ³ 1.0 x 109/L, platelet count ³ 100 x 109/L; in case of bone marrow disease: ³ 75 x 109/L; hemoglobin ³ 8 g/dLAdequate renal function: creatinine £ 1.5 x ULN for age; If serum creatinine is , 1.5 ULN of age, then creatinine clearance (or radioisotope GFR) must be , 70 ml/min/1.73 m2Adequate hepatic function: bilirubin £ 1.5 x ULN; ASAT and ALAT £ 2.5 x ULN (ASAT, ALAT ≤5xULN in case of liver metastases ...
Health,A new study finds that longer courses of a mild form of chemotherapy m...MDS is a bone marrow disease that causes an increasing number of dysfu...MDS generally afflicts adults over 50 years old and therapy is suppor...Little is known about the optimal duration of treatment with decitabin...,Study,recommends,treatment,change,for,pre-leukemia,disease,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
High RBC is often related to low oxygen level, dehydration, kidney disease, bone marrow disease. You doctor may test your oxygen saturation, its an easy test and it takes a few seconds to know. Your value is slightly high, I would suggest a second test sometime later and make sure youre hydrated before the test ...
RATIONALE: Biopsy of sentinel lymph nodes and bone marrow may improve the ability to detect and determine the extent of cancer. PURPOSE: Phase II
Introduction: Gastric cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancer related death worldwide. There are two types of gastric carcinoma: intestinal, characterized by cohesive tumor cells arranged in glandular formation, and diffuse, which is poorly cohesive with crescent-shaped eccentric nuclei. The diffuse type of gastric carcinoma, including signet cell carcinoma, is common in patients less than 50 years of age and is associated with advanced disease and poor prognosis. Diffuse type of carcinoma mostly found in patients without classic risk factors for gastric carcinoma such as untreated H. Pylori, or smoking history. Signet cell carcinoma has a high rate of bone marrow metastasis, and can present with severe cytopenias. Once bone marrow metastasis is diagnosed, average life expectancy is 11 to 121 days. Though the global incidence of gastric carcinoma has declined since 1970, incidence of diffuse-type carcinoma has increased by ten-fold. Case presentation: A
History: 6 year old male with abdominal pain Unfortunately, this is a case of metastatic neuroblastoma in a 6 year old male which was diagnosed initially on MRI. Neuroblastoma is the most common extracranial solid malignancy in children, and the third most common overall cancer in children. They most commonly arise from the adrenal medulla…
TY - JOUR. T1 - Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?. AU - Di Cataldo, A.. AU - Agodi, A.. AU - Balaguer, J.. AU - Garaventa, A.. AU - Barchitta, M.. AU - Segura, V.. AU - Bianchi, M.. AU - Castel, V.. AU - Castellano, A.. AU - Cesaro, S.. AU - Couselo, J. M.. AU - Cruz, O.. AU - DAngelo, P.. AU - Bernardi, B.. AU - Donat, J.. AU - de Andoin, N. G.. AU - Hernandez, M. I.. AU - Spina, M.. AU - Lillo, M.. AU - Lopez-Almaraz, R.. AU - Luksch, R.. AU - Mastrangelo, S.. AU - Mateos, E.. AU - Molina, J.. AU - Moscheo, Carla. AU - Mura, Rosamaria. AU - Porta, F.. AU - Russo, G.. AU - Tondo, Annalisa. AU - Torrent, M.. AU - Vetrella, Simona. AU - Villegas, J. A.. AU - Viscardi, E.. AU - Zanazzo, G. A.. AU - Canete, A.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - INTRODUCTION: SIOPEN INES protocol yielded excellent 5-year survival rates for. AB - INTRODUCTION: SIOPEN INES protocol yielded excellent 5-year survival rates ...
Tumor cell dissemination in bone marrow or other organs is thought to represent an important step in the metastatic procedure. agents also to progress our knowledge of the biology of metastasis. Intro Breast cancers (BC) may be the most common tumor in ladies in European countries [1]. Despite medical procedures and adjuvant systemic therapy a lot of women with early BC still relapse and perish of their disease. Minimal residual disease (MRD) after possibly curative medical procedures for BC can be thought to donate to disease relapse also to be the prospective of adjuvant treatment. MRD is thought as micrometastatic cells undetectable by conventional lab and imaging testing. Surrogates of MRD are tumor cells recognized in the bone tissue marrow (disseminated tumor cells (DTCs)) and peripheral bloodstream (circulating tumor cells (CTCs)) [2]. The recognition and characterization of DTCs/CTCs are anticipated to result in customized treatment strategies and speed up the introduction of novel ...
PET-CT has a high sensitivity when assessing marrow infiltration in pediatric malignancies. Advances in radiologic modalities may obviate the use of invasive, painful, and costly procedures like BMB. Furthermore, biopsy results are limited by insufficient tissue or the degree of marrow infiltration …
Our team works tirelessly to ensure Lebanese people have a reliable alternative to the politically-backed media outlets with their heavily-funded and dangerous propaganda machines. Weve been detained, faced nonstop cyber attacks, censorship, attempted kidnapping, physical intimidation, and frivolous lawsuits draining our resources. Financial support from our readers keeps us fighting on your behalf. If you are financially able, please consider supporting The961s work. Support The961. Make a contribution now. ...
In multiple myeloma, the tumor cells mainly reside in the bone marrow, where they bind to stromal cells and induce the secretion of cytokines. Among them, IL-6 is one of the most important factors mediating multiple myeloma cell growth, survival, and drug resistance (9, 10). The gp130 signal transducer chains of the IL-6R complex are constitutively associated with JAK kinases, which play a critical role in IL-6-mediated cellular response (11). Evidence for JAK activation in multiple myeloma cells in vivo comes from studies showing constitutive activation of STAT3 in tumor samples, whereas little or no activated STATs were detected in bone marrow from normal individuals or patients with no evidence of bone marrow metastases (30-32). Here, we show that the selective JAK inhibitor INCB20 induces cytotoxicity in multiple myeloma cells by blocking IL-6 signaling pathways.. Inhibition of cell growth by INCB20 was achieved in nine multiple myeloma cell lines; sensitivity to INCB20 treatment, however, ...
Established from a bone marrow metastasis of a 42-month-old boy with stage IV neuroblastoma after 6 months of chemotherapy. IFN gamma inhibits growth of GIMEN. FGF-2 is antimitogenic for GIMEN cells, this antimitogenic effect of FGF-2 is reversed by IFN gamma and enhanced by IL-1 beta ...
Established from the bone marrow metastasis of a 17-year-old man with undifferentiated (standard classification) or unclassified (Palmer classification) alveolar rhabdomyosarcoma; cells were described as carrying a p53 mutation, expressing high levels of both myogenin and myoD, and expressing the Pax3/FKHR fusion protein secondary to the t(2;13)(q35;q14) ...
Rao, Indu R and Prabhu, Ravindra A and Rangaswamy, Dharshan and Shenoy, Srinivas Vinayak and Laxminarayana, Sindhura LK and Nagaraju, Shankar Prasad (2019) Efficacy and safety of a modified- modified Ponticelli regimen for treatment of primary membranous nephropathy. Journal of Nephropathology, 8 (3). pp. 1-6. ISSN 2251-8363 Singh, Varun Kumar and Vijay, Anjali S and Belurkar, Sushma V and Amber, Shiny (2019) Prognostic information from chemotherapy-associated changes in bone marrow metastasis of neuroblastoma- a case report. Indian Journal of Applied Research, 9 (6). pp. 7-9. ISSN 2249 - 555X Rao, Raghavendra and Pai, Kanthilatha (2019) Multiple asymptomatic lesions on the lips. Clinical and Experimental Dermatology, 44. pp. 316-318. ISSN 0307-6938 Khanna, Vinay and Ashraf, Asem Ali and Khanna, Ruchee (2019) Echinostomiasis in a child with severe anemia. Tropical Parasitology, 9 (1). pp. 54-56. ISSN 2229-5070 Shanthi, P B and Faruqi, Faraz and Hareesha, K S and Kudva, Ranjini (2019) Deep ...
OUTLINE: This is a dose-escalation study.. Patients receive oral beta-glucan and monoclonal antibody 3F8 (MOAB 3F8) IV within 1.5 hours on days 1-5 and 8-12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.. Cohorts of 6 patients receive escalating doses of beta-glucan and MOAB 3F8 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.. Patients are followed monthly for 6 months, every 2 months for 6 months, and then every 3-6 months for 2 years.. PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for this study within 2 years. ...
There is increasing evidence that the presence of CTCs and DTCs is correlated with minimal residual disease or disease progression in patients with breast cancer. Nevertheless, the underlying molecular characteristics of micrometastatic cells associated with the development of overt metastases remain largely unknown. EMT is a multistep process that has been suggested to play a key role in cancer progression and metastasis [12]. Accordingly, CTCs bearing characteristics of an EMT phenotype should be actively involved in tumour dissemination, proliferation and metastasis. Twist is a transcription factor that, among others, participates in EMT and is upregulated in many tumour cells [18-22, 47]. In a recent report by Watson et al. [24], Twist expression was specifically enhanced in a gene signature obtained from epithelial cell adhesion molecule-enriched bone marrow samples of patients with breast cancer after neoadjuvant chemotherapy. Twist also increases VEGF expression, while it is directly ...
and it has an unknown cause. What happens? Well, cells in the bone marrow start putting out tons of misfolded proteins. These buggers settle in the organs, like the heart, kidney, liver, and digestive tract, gradually gumming up the works and leading to the failure of the affected organ(s). They can also settle in other tissues, like the tongue, salivary glands, body fat, etc. Untreated, the disease progresses rapidly, and death usually occurs in a couple of years. The other outcome is that I was forced into retirement from my psychotherapy practice, but as you will see, it led me to another purpose.. While not strictly a cancer, amyloidosis is treated very much like its cousin multiple myeloma, another bone marrow disease. I was lucky enough that, the disease having been identified relatively early in its progression, none of my major organs had been strongly impacted. Actually, the big tip-off was my very enlarged tongue. Macroglossia, as its called, is a symptom that occurs in fewer than ...
Good Morning America co-host Robin Roberts will take a leave of absence from the show late next month to undergo a bone marrow transplant. Roberts was diagnosed with bone marrow disease earlier in the year.. The 51-year-olds recent health battles reportedly stem after complications from successful breast cancer treatment. Over the past few months Roberts said she has battled moments of fatigue and feels its time to address her health.. Its fascinating-slash-scary how to prepare yourself for something like this, Roberts told reporters via satellite during an ABC panel at the Television Critics Association press tour.. Roberts said GMAs recent surge in momentum has revitalized her, but she still felt the need to take a break from the show. ...
Today more than 70 diseases are being treated using stem cells and the possibilities for these remarkable cells keep growing. Im not alone when I tell you that in the future stem cells will be used to cure and treat diseases now fatal or disabling. Stem cell discoveries in the 21st century will be like the antibiotic boom in the last century.. The reason for the explosion in stem cell research is because these cells have the remarkable ability to develop into almost any type of cell in the body. Its a complicated process, but after years of successful research, stem cells are now considered standard therapy in the treatment of many serious diseases such as leukemia, lymphoma, some bone marrow diseases like multiple myeloma and some immune system diseases. And the list is growing. ...
Deletions and dominant-negative mutations in IKZF1, the gene encoding Ikaros transcription factor, are found in ∼85% of Ph+ B-ALL and in some cases of Ph− B-ALL, and are associated with poor prognosis. Genomic studies of high-risk Ph− or Ph-like B-ALLs have revealed frequent mutation and activation of TK genes and signaling pathways. While ABL1 tyrosine kinase inhibitors (TKIs) such as dasatinib and ponatinib have been incorporated into chemotherapy regimens for Ph+ B-ALL, the majority of patients still relapse, which correlates with residual bone marrow disease following induction therapy. New therapeutic strategies are needed for patients with Ikaros-mutant, high-risk Ph+ and Ph− B-ALL.. Using mice with a conditional Ikzf1 mutation (Ike5fl) that mimics the dominant-negative Ik6 mutant found in human B-ALL, we demonstrated that loss of Ikaros DNA-binding function arrests B-lymphoid development at a large pre-B cell stage that can give rise to B-ALL. Survival and proliferation of ...
1750 - The first Shakespearean play in America, King Richard III, was presented at the Nassau Street Theatre in New York City.. 1961 - Zeke Mowatt was born. He became a tight end in the NFL and played for the New York Giants from 1983 to 1989 before being traded to the New England Patriots in 1991. He came back to the Giants to finish his career in 1991.. 1970 - The Weathermen terrorist group bombed 18 West 11th St. in New York, N.Y.. 1999 - Broadways original Man of La Mancha, actor Richard Kiley, died at age 76 of bone marrow disease in Warwick, N.Y... ...
Some of you will certainly comment on the higher prices at Hanjip, but after splitting the bill, the meal cost is similar to going to Genwa or other high end KBBQ places, and I very much enjoyed everything Ive tried here. Hanjip is definitely the best Korean BBQ option on the Westside (the only option?) but its become one of the top in the city as well. They have $12 lunch items, as well, if you wanted to try out the places for less first ...
Metastasis from the primary tumor to distant organs is the principal cause of mortality in patients with cancer. While prognostic factors can predict which patients are likely to have their cancer recur, these are not perfect predictors, and some patients cancers recur even decades after apparently …
TY - JOUR. T1 - Detection of metastatic neuroblastoma in bone marrow biopsy specimens with an antibody to neuron-specific enolase.. AU - Crary, G. S.. AU - Singleton, T. P.. AU - Neglia, J. P.. AU - Swanson, P. E.. AU - Strickler, J. G.. PY - 1992/5. Y1 - 1992/5. N2 - To verify the practical utility of immunohistochemical analysis of bone marrow biopsy specimens in patients with neuroblastoma, we compared the results of routine histologic examination of 68 specimens with the results of immunohistochemical detection of tumor cells using an antibody to neuron-specific enolase (NSE). A commercially available polyclonal antibody to this enolase isoform consistently reacted with the neoplastic cells in biopsy specimens with histologic features diagnostic of (24 specimens) or suspicious for (one specimen) metastatic neuroblastoma. Immunohistochemical double-staining techniques documented that the NSE-positive neoplastic cells also reacted with antibodies to chromogranin and synaptophysin. Notably, ...
Aims and Objectives: Patients were divided into two groups, 30 patients with bone marrow infiltration (group B) and remaining without infiltration (group C). The values were compared with 20 healthy age and sex matched contrtols (groupA). The estimations were made prior to the institution of chemotherapy ...
Hands on Health-South Carolina is designed to promote healthier citizens and communities in South Carolina. It focuses on health issues and problems important in the state. The site has been developed collaboratively by the Medical University of South Carolina Library working with the University of South Carolina School of Medicine Library, the South Carolina State Library and the South Carolina Hospital Association. It provides links to high quality websites that are easy to navigate and provide appropriate and useful information. The information is intended for the use of laypersons not health professionals and is presented in a format that people of all age groups reading abilities and education levels will be able to comprehend. The Medical University of South Carolina Library received funding for the project from the Duke Endowment.
https://doi.org/10.18632/oncotarget.3745 Sara Stigliani, Paola Scaruffi, Corrado Lagazio, Luca Persico, Barbara Carlini, Luigi Varesio, Fabio Morandi, Martina Morini, Anna Rita Gigliotti, Maria...
The above is an informational video that explains the basics of Aplastic Anemia & introduces you to a few of the people affected by it.). Symptoms of Aplastic Anemia. So What is Aplastic Anemia?. Medical Definition: Aplastic anemia is a degenerative bone marrow disease. It is a rare and serious condition in which the bone marrow stops producing enough platelets, red and white blood cells to keep the body healthy, resulting in an increased risk of infection and uncontrollable bleeding.. Parents Definition: A condition which causes your child to become sleepy, clingy and irritable. An instant crash course in at-home nursing for parents. Also known to make others think you abuse your children due to excessive bruising and bad attitude.. Aplastic Anemia (AA) is one of those diseases you never hear of until you or your loved one is diagnosed with it. There are around 300~400 cases diagnosed every year in the United States, around 1 in a million. It is a very serious condition that doctors are not ...
In November 2016 Schmoul was diagnosed with Systemic Mastocytosis, a rare bone marrow disease. Despite how he felt or how far he could still ride Lucy, the doctors told him that he was indeed very ill and would require chemotherapy and a stem cell replacement. As what frequently happens in life, our plan is not necessarily Gods plan. Schmoul began taking an experimental oral chemo drug, Midostaurin, in March 2017. The drug was approved by the FDA in April and Schmoul has continued on it. Unfortunately, it has not been the miracle worker we had hoped for. It appeared to decrease the Mast Cells in the bone marrow but his organs (spleen and liver) continue to grow larger. As a result, the stem cell transplant is on hold until we find a treatment that will debulk the spleen.
A new study finds that longer courses of a mild form of chemotherapy may help patients with a bone marrow disease only recently considered a form of cancer. Writing in the April 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, researchers say the study found that 45 percent of patients with Myelodysplastic Syndrome (MDS) who relapse did respond to a second course of treatment, but that the quality and duration of the second response was inferior to the initial treatment, leading researchers to believe that longer initial treatments may be more beneficial to patient outcome.. Myelodysplastic Syndrome ...
Like Pourhouse, they cut the bone into three sections and provided a butter knife and a small spoon. I had to give up the spoon early because it was too wide to fit, so I couldnt use it to scoop out any marrow. Fortunately, the butter knife worked out nicely: I used it on the inside surface of the bone to loosen the marrow from the bone, and a bit of light shaking caused the marrow to come out more or less intact ...
Neuroblastoma is a highly malignant tumor of children that arises in the peripheral sympathetic nervous system, and spreads widely to bones and bone marrow. The survival of children with metastatic neuroblastoma is less than 40%, despite intensive chemotherapy, radiation and bone marrow transplant. Metaiodobenzylguanidine (MIBG) is a chemical similar in structure to noradrenaline and specifically taken up by neuroblastoma, thus providing a means to detect tumor metastases and to deliver intravenous tumor-targeted radiation by attaching a radioactive iodine molecule. 131I-MIBG has achieved responses of 40% in children with relapsed neuroblastoma, with very few side effects, but due to the special requirements of administering radioactive medicines, is used at only a few centers and is not yet approved for commercial use by the FDA. Furthermore, there is very little pre-clinical data on using MIBG in combination with the new molecularly targeted drugs to provide a platform for overcoming resistant ...
모체의 혈청 내 호모시스테인 수준은 태아 성장에 중요한 요인으로 부각되고 있으며 영아의 정상적인 발달과 성장을 위하여 비타민 B₂, 비타민 B_(6), 엽산, 비타민 B_(12) 영양상태가 중요한 것으로 알려져 왔다. 본 연구에서는 생후 12개월 영아의 성장에 관련성이 있을 것이라 사료되는 모체의 임신 중반기의 혈청 호모시스테인 수치와 혈청 비타민 B군 수준, 영아의 비타민 B군 섭취상태에 따른 영아의 성장 발달을 살펴보았다. 또한 영아의 수유상황과 보충제 복용유무, 질병실태에 따른 영아의 영양섭취상태와 성장을 살펴보았다. 이 연구는 전향적 코호트 연구로서 기존에 E 대학 병원 산부인과에서 임신 24-28주의 임산부 308명을 대상으로 이루어졌다. 이들에게서 태어난 영아들 중 생후 1년째의 영아 110명을 대상으로 신체 계측을 실시하고, 식이섭취조사와 ...
To prepare for this falls Best of Dallas® 2012 issue, were counting down (in no particular order) our 100 Favorite Dishes. If theres a dish you think we should try, leave it in the comments, or email me. Meddlesome Moths menu takes some careful navigation. The mussels are a safe...
Full text for this publication is not currently held within this repository. Alternative links are provided below where available. ...
Myeloperoxidase (MPO) is an heterodimeric glycoprotein of 150 kDa with an α2/β2 structure. The two subunits (α and β) have a molecular weight of 55 and 15 kDa, respectively. MPO synthesis occurs in bone marrow at an early stage of myeloid lineage differentiation.
Announcing a New Architecture Field: Control Flow Advantages: No loads or stores=> simple memory system No I/O beyond single LED Start a new sequence of courses & new journal on Theory & Practice of Control Flow B B B B B B B B B B B B B B B B A B A A B A A B A A B A B B B B B B B B B B B B B B B B B B B B B B B B B B B B ...
Principal Investigator:MIYAZAKI Tatsuya, Project Period (FY):2010-04-01 - 2015-03-31, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Digestive surgery
MPNs are a group of rare blood cancers which can often remain stable or progress quite slowly, but can present many challenges for those living with them. Here, Jane shares her experience of the disease and her advice for those who have recently been diag
Luas bmb=luas rumpun bambu, Jml jns sm=jumlah spesies semai, Jml jns pnc=jumlah spesies pancang, Jml ind pnc=jumlah individu pancang, Jml jns tg=jumlah spesies tiang, Jml ind tg=jumlah individu tiang, Jml jns phn=jumlah individu pohon, Jml ind phn=jumlah individu pohon, Jml jns bmb=jumlah spesies bambu, Jml ind bmb=jumlah rumpun bambu, lux=intensitas cahaya, %udara=kelembaban udara, %tanah=kelembaban tanah, lereng=kelerengan, Altd=ketinggian tempat/altitude. ...
... even though all blood cells are normally produced in the marrow in adults). Myeloid neoplasms always concern bone marrow cell ... Myeloid tissue, in the bone marrow sense of the word myeloid (myelo- + -oid), is tissue of bone marrow, of bone marrow cell ... or resembling bone marrow, and myelogenous tissue (myelo- + -genous) is any tissue of, or arising from, bone marrow; in these ... Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA (2012). "Lin28b reprograms adult bone marrow hematopoietic progenitors to ...
Leukaemias are subdivided into lymphoid and myeloid neoplasms, depending on which bone marrow cells are cancerous. The myeloid ... which are cancers of the blood-forming cells of the bone marrow. In adults, blood cells are formed in the bone marrow, by a ... Bone marrow core biopsies may show a predominance of myelocytic and monocytic cells, abnormal localisation of immature ... The FAB criteria for diagnosis are as follows: Monocyte count >1x109/L 0-19% blasts in bone marrow 1x109/L No Philadelphia ...
All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, ... The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone ... Cellular phase - increased large megakaryocytes with fibrosis and little increase in other bone marrow elements ... Although not a malignant neoplasm like other cancers, MPNs are classified within the hematological neoplasms. There are four ...
... and a number of neoplasms of the bone marrow. Causes of increased breakdown include genetic conditions such as sickle cell ... In manual examination, activity of the bone marrow can also be gauged qualitatively by subtle changes in the numbers and the ... Even where the source of blood loss is obvious, evaluation of erythropoiesis can help assess whether the bone marrow will be ... A reticulocyte count is a quantitative measure of the bone marrow's production of new red blood cells. The reticulocyte ...
... is an uncommon myeloproliferative neoplasm in which the bone marrow makes too many red blood cells. It may ... Bone marrow transplants are rarely undertaken in people with polycythemia; since this condition is non-fatal if treated and ... was used as another means to suppress the bone marrow. Such treatment is now avoided due to a high rate of AML transformation. ... red cell mass arterial oxygen saturation abdominal ultrasound serum erythropoietin level bone marrow aspirate and trephine ...
In cases of a supposed myeloid neoplasm, a bone marrow biopsy will be performed utilizing cytogenetic analysis. This type of ... A bone marrow aspirate may be utilized to confirm an increase in basophils or significantly high numbers of precursors to the ... The root cause of basophilia can be determined through a bone marrow biopsy, genetic testing to look for genetic mutations, or ... Elevation of basophils may also be representative of multiple other underlying neoplasms such as polycythemia vera (PV), ...
... is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the bone marrow. Acute Lymphoblastic Leukemia ( ... Bone marrow consists of a combination of solid and liquid components. Bone marrow aspiration and biopsies are typically done ... Patients often present extensive bone marrow involvement, mediastinal mass, adenopathy, CNS involvement, and splenomegaly. ... ALL) is a condition where immature white blood cells accumulate in the bone marrow, subsequently crowding out normal white ...
... bone marrow neoplasms MeSH C15.378.420.155 - anemia, sickle cell MeSH C15.378.420.155.440 - hemoglobin sc disease MeSH C15.378. ... bone marrow neoplasms MeSH C15.378.190.625 - myelodysplastic syndromes MeSH C15.378.190.625.062 - anemia, refractory MeSH ... splenic neoplasms MeSH C15.604.744.742 - splenic rupture MeSH C15.604.744.742.500 - splenosis MeSH C15.604.744.909 - ...
... white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the ... However, a bone marrow biopsy will show reticulin and/or collagen fibrosis with a grade 2 or 3. Anemia, splenomegaly, LDH above ... High hemoglobin or hematocrit counts are required, as is a bone marrow examination showing "prominent erythroid, granulocytic ... of the myeloid lineages in the bone marrow develop somatic mutations which cause them to grow abnormally. There is a similar ...
Other less common sites of origin include the prostate, kidney, thyroid, skin, colon and blood or bone marrow. Tumors in the ... Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be ...
... and bone marrow). This latter form of HS is most like malignant histiocytosis (MH). MH is an aggressive, histiocytic neoplasm ... Primary lesions of HS occur in spleen, lymph node, lung, bone marrow, skin and subcutis especially of extremities. Secondary ... Hemophagocytic HS does not initially form mass lesions in the primary sites (spleen and bone marrow). Typically, diffuse ... Histiocytic lesions have been observed in skin, lung, liver, bone marrow, spleen, peripheral and visceral lymph nodes, kidneys ...
... and bone marrow and evidence (i.e. cytopenias) of bone marrow failure. Blastic plasmacytoid dendritic cell neoplasm has a high ... Unlike conventional dendritic cells (cDCs) that leave the bone marrow as precursors, pDCs leave the bone marrow to go to the ... In the bone marrow, common dendritic cell progenitors expressing Flt3 (CD135) receptors are able to give rise to pDCs. Flt3 or ... They develop from bone marrow hematopoietic stem cells and constitute < 0.4% of peripheral blood mononuclear cells (PBMC). ...
Intraocular, into the eye, e.g., some medications for glaucoma or eye neoplasms. Intraosseous infusion (into the bone marrow) ... is, in effect, an indirect intravenous access because the bone marrow drains directly into the venous system. This route is ...
No evidence of iron deficiency stainable iron in the bone marrow or normal red cell mean corpuscular volume B3. No evidence of ... It is one of four myeloproliferative neoplasms (blood cancers) that occur when the body makes too many white or red blood cells ... by megakaryocytes in the bone marrow. It may, albeit rarely, develop into acute myeloid leukemia or myelofibrosis. ... ET is the myeloproliferative neoplasm least likely to progress to acute myeloid leukemia.[citation needed] The incidence of ET ...
... bone marrow (~65% of cases) and cerebrospinal fluid (47% of childhood cases but less often detected in adult cases). More ... and/or leukopenia due to extensive malignant pDC infiltrations in the bone marrow. A leukemic phase of the disease is a common ... malignant plasmacytoid dendritic cells in blood and bone marrow). While commonly presenting with these clinical features, BPDCN ... The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females ...
While the bone marrow is commonly involved, the detection of the neoplastic infiltrate may be difficult due to a diffuse, ... It is a systemic neoplasm comprising medium-sized cytotoxic T-cells that show significant sinusoidal infiltration in the liver ... The spleen and liver are always involved, and bone marrow involvement is common. Nodal involvement is exceedingly rare. The ... citation needed] Autologous bone marrow transplantation is currently being investigated. Hepatosplenic lymphoma is rare, ...
Rosa initially had planned to participate at the 10K on behalf of a 9-year-old patient, who was recovering from a bone marrow ... He followed several alternative treatments, such as high vitamin C doses or neoplasm treatment at the Burzynski Clinic in ... On February 26, Draco commenced his second bone marrow transplant in California and remained in quarantine for a course of four ... On December 9, 2013, Rosa's manager confirmed his cancer had relapsed and overcame cancer once again after a second bone marrow ...
... and bone marrow and evidence (i.e. cytopenias) of bone marrow failure. Blastic plasmacytoid dendritic cell neoplasm has a high ... The monocytes in turn are formed from stem cells in the bone marrow. Monocyte-derived dendritic cells can be generated in vitro ... Blastic plasmacytoid dendritic cell neoplasm is a rare type of myeloid cancer in which malignant pDCs infiltrate the skin, bone ... Dendritic cells are derived from hematopoietic bone marrow progenitor cells. These progenitor cells initially transform into ...
On both the bone marrow aspirate and the core biopsy, a hypercellular marrow with an increased myeloid:erythroid ratio of 20:1 ... Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent neutrophilia in peripheral ... Peripheral blood, bone marrow, spleen, and liver are most common, but any organ or tissue can be infiltrated by neutrophils. ... There is a reported association between CNL and multiple myeloma, so the bone marrow biopsy may show evidence of a plasma cell ...
Bone Marrow Biopsy Chapter CP17: Clinical Procedures Tutorial: Basic Suturing Clinical Information Access Portal List of ... Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Bone Marrow Failure Syndromes Including Aplastic Anemia and Myelodysplasia Chapter 99: Polycythemia Vera and Other ... Disorders of Bone and Mineral Metabolism Chapter 402: Bone and Mineral Metabolism in Health and Disease Chapter 403: Disorders ...
Other less common sites of origin include the prostate, kidney, thyroid, skin, colon and blood or bone marrow. ... Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be ... Retrieved from "https://en.wikipedia.org/w/index.php?title=Eye_neoplasm&oldid=895356793" ...
The expanding population of eosinophils initially formed in the bone marrow may spread to the blood and then enter into and ... lymphoid neoplasms, or features of both types of neoplasms. Most commonly, the present with features of myeloid neoplasms with ... In most but not all instances, the resulting malignancies are associated with increases in blood, bone marrow, and/or tissue ... Currently, treatment with chemotherapy agents followed by bone marrow transplantion has been used to improve survival. The ...
Boyer, DF (October 2016). "Blood and Bone Marrow Evaluation for Eosinophilia". Archives of Pathology & Laboratory Medicine. 140 ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ... Boyer DF (2016). "Blood and Bone Marrow Evaluation for Eosinophilia". Archives of Pathology & Laboratory Medicine. 140 (10): ... such as bone marrow aspiration and biopsy for the leukemias, MRI/CT to look for solid tumors, and tests for serum LDH and other ...
A bone marrow biopsy will reveal collagen fibrosis, replacing the marrow that would normally occupy the space.[citation needed ... It is classified by the World Health Organization (WHO) as a type of myeloproliferative neoplasm, a group of cancers in which ... The bone marrow in a typical case is hypercellular and diffusely fibrotic. Both early and late in disease, megakaryocytes are ... Diagnosis is made on the basis of bone marrow biopsy. Fibrosis grade 2 or 3 defines overt PMF whereas grade 0 or 1 defines ...
... increased numbers of bone marrow eosinophils, and/or the infiltration of eosinophils into tissues. These neoplasms were ... and require treatment with chemotherapy agents followed by bone marrow transplantion in order to improve survival. The tyrosine ... The Fgfr1 gene appears critical for the truncation of embryonic structures and formation of muscle and bone tissues and thereby ... Unlike many other myeloid neoplasms with eosinophil such as those caused by Platelet-derived growth factor receptor A or ...
... each of which develops from cells originating in mesenchymal cells outside the bone marrow. ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... For certain types of cancer, such as early head and neck cancer, it may be used alone.[155] For painful bone metastasis, it has ... Physical trauma resulting in cancer is relatively rare.[64] Claims that breaking bones resulted in bone cancer, for example, ...
Bone marrow examination may reveal cellular features similar to that seen in the aforementioned diseases. Diagnosis is may by ... This continuous signaling, it is presumed, leads to the development of myeloid and/or lymphoid neoplasms that commonly include ... Other genetic abnormalities in PDGFRB lead to various forms of potentially malignant bone marrow disorders: small deletions in ... conventional cytogenetic examination of blood or bone marrow cells to test for PDGFRB rearrangements using Fluorescence in situ ...
Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. ... trophoblastic neoplasms, and ovarian carcinoma. Moreover, it also has been used as an immunosuppressive drug for various ... Common side effects include bone marrow suppression. Other serious side effects include an increased long term risk of further ...
... pulmonary megakaryocytes migrate out of lungs into the bone marrow, where they help to replenish the depleted bone marrow ... EMH in the lymph nodes is usually associated with underlying hematopoietic neoplasms. Myeloproliferative neoplasms (MPNs) tend ... Finally, once the bone marrow has developed, they migrate there. They can also migrate to the spleen and lymph nodes where ... The cause of pathologic EMH can be one of many hematological diseases, such as myelofibrosis, or as a result of bone marrow ...
... or bone marrow The presence of an extramedullary proliferation of blasts The only curative treatment for CML is a bone marrow ... May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. ... It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the ... CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes (neutrophils, eosinophils and ...
Bone marrow niche / extracellular matrix disruption in myeloproliferative neoplams. Myeloproliferative neoplasm-associated bone ... Bone marrow niche dysregulation in myeloproliferative neoplasms Message Subject (Your Name) has forwarded a page to you from ... Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J Exp Med. 2015;212(5):759-774. ... Direct or indirect targeting of the bone marrow niche in myeloproliferative neoplasms: is there a role?. To date, the only ...
Figure 2.Bone marrow (BM) anatomy. The normal bone marrow anatomy (here using the example of the femur) is composed of ... bone marrow and spleen. However, when wild-type bone marrow was transplanted into these mice, the recipient mice, also ... as diagnoses are primarily made on bone marrow aspirates that disrupt bone marrow architecture. Therefore, xenogeneic models ... A hostel for the hostile: the bone marrow niche in hematologic neoplasms ...
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.. W S Pear, ... Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. ... Using a bone marrow reconstitution assay with cells containing retrovirally transduced TAN1 alleles, we analyzed the oncogenic ... Moreover, the murine tumors caused by TAN1 in the bone marrow transplant model are very similar to the TAN1-associated human ...
Standards Reporting Form: Bone Marrow Synoptic Reporting for Hematologic Neoplasms - CAP US ... BoneMarrow_CAP - GIN Library - Standards Reporting Form -v6 0.pdf - PDF document, 391 kB (400,596 bytes) ...
Stephen Oh discuss their views on when and why patients should have a bone marrow biopsy. ... How often should MPN patients have a bone marrow biopsy? Dr. Brady Stein and Dr. ... How often should MPN patients have a bone marrow biopsy? Dr. Brady Stein and Dr. Stephen Oh discuss their views on bone marrow ... then we discuss the option of a bone marrow biopsy. We offer it. Now, when I offer a bone marrow biopsy, of course, thats not ...
Secondary malignant neoplasm of bone and bone marrow information including symptoms, causes, diseases, symptoms, treatments, ... Bone and bone *Malignant neoplasm *Bone marrow *Bone marrow symptoms *Bone marrow disease *Bone marrow disorder *Malignant * ... Neoplasm (16 causes) *Neoplasm pain *Bone Hierarchical classifications of Secondary malignant neoplasm of bone and bone marrow ... Secondary malignant neoplasm of bone and bone marrow: Related Topics. These medical condition or symptom topics may be relevant ...
Carla nasceu em Viana do Castelo em 1977. Licenciada em Anatomia Patológica, Citológica e Tanatológica pela Escola Superior de Tecnologia da Saúde em Lisboa. Concluiu a certificação em Laboratory Management pela ASCP (American Association of Clinical Pathology) em Setembro de 2016. Mestre em Genética Molecular e Biomedicina pela Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa. Trabalhou no Centro Hospitalar Lisboa Central entre 1998 e 2015, exercendo histopatologia e imunohistoquímica, sendo co-responsável pelo sector. Trabalha no Dr. Joaquim Chaves, Laboratório de Anatomia Patológica desde 2004 onde exerce funções de Coordenação Técnica e da Qualidade.. ...
Evidence-based guideline provides a framework for a synoptic format for clear bone marrow reporting to advance patient ... The evidence-based guideline "Bone Marrow Synoptic Reporting for Hematologic Neoplasms" provides a framework for a synoptic ... Considering the possible ancillary studies that could be ordered on a bone marrow specimen, which ones are required on a ... The guideline tackles the complexities of the bone marrow organ and establishes an evidence-based framework that laboratories ...
However, the role of ,i,RTEL1,/i, mutations in other bone marrow failure (BMF) syndromes and myeloid neoplasms, and the ... Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms Judith C W Marsh 1 2 , Fernanda Gutierrez-Rodrigues 3 ... Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms Judith C W Marsh et al. Blood Adv. 2018. . ... However, the role of RTEL1 mutations in other bone marrow failure (BMF) syndromes and myeloid neoplasms, and the contribution ...
... in order to evaluate their bone marrow morphology and identify possible associations between histological findings and clinical ... We examined a consecutive series of 29 patients with myeloproliferative neoplasms (MPNs) associated with splanchnic vein ... Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms ... Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms ...
Metastatic Neoplasm to the Bone Marrow): Read more about Symptoms, Diagnosis, Treatment, Complications, Causes and Prognosis. ... Bone Marrow with Tumor Cells. *For histologic tissue sections, bone is stained green, whereas bone marrow and tumor cells ( ... Hypercellular Bone Marrow. *The pathological findings of resected rib bones exhibited hypercellular bone marrow without excess ... When it does occur, signs and symptoms of bone metastasis include: Bone pain Broken bones Urinary incontinence Bowel ...
Orbital Rhabdomyosarcoma Infiltrating the Bone Marrow: A Potential Mimic of a Haematopoietic Neoplasm Authors (first, second ... Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy Authors (first, ...
Novel Blood Biomarkers for Predicting Bone Marrow Failure in Myeloproliferative Neoplasms. *Guo, Belinda (Chief Investigator) ...
"The bone marrow stroma in hematological neoplasms-a guilty bystander.",. abstract = "In the setting of hematological neoplasms ... The bone marrow stroma in hematological neoplasms-a guilty bystander.. Claudio Tripodo, Giovanni Franco, Stefano A. Pileri, ... The bone marrow stroma in hematological neoplasms-a guilty bystander. / Tripodo, Claudio; Franco, Giovanni; Pileri, Stefano A ... The bone marrow stroma in hematological neoplasms-a guilty bystander. In: NATURE REVIEWS. CLINICAL ONCOLOGY. 2011 ; Vol. 8. pp ...
Tissue: blood bone marrow / haematopoietic and lymphoid tissue ...
Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. In: ... Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. / ... Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. ... T1 - Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms ...
Neoplasms by Histologic Type. Neoplasms. Hematologic Diseases. Bone Marrow Diseases. Precancerous Conditions. Leukemia, Myeloid ... MDS: Patients must have , 10% marrow blasts; fewer than 10% marrow blasts must be documented by marrow examination within 3 ... MPD: Patients must have , 10% marrow blasts; fewer than 10% marrow blasts must be documented by marrow examination within 3 ... Atypical CML: Patients must have , 10% marrow blasts; fewer than 10% marrow blasts must be documented by marrow examination ...
Bone Marrow Neoplasms. Hematologic Neoplasms. Neoplasms by Site. Neoplasms. Bone Marrow Diseases. Myeloproliferative Disorders ...
Bone Marrow Neoplasms. Hematologic Neoplasms. Neoplasms by Site. Neoplasms. Bone Marrow Diseases. Myeloproliferative Disorders ... As the disease progresses the size of spleen and liver increased in most cases and the bone marrow shows signs of fibrosis. In ... Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and ...
Bone Marrow Diseases. Hematologic Diseases. Bone Marrow Neoplasms. Hematologic Neoplasms. Neoplasms by Site. Blood Platelet ... CONSOLIDATION: Patients that have =, 5% blasts in bone marrow receive CPX-351 IV on days 1 and 3 and ruxolitinib PO BID on days ... MAINTENANCE THERAPY: Patients who successfully complete consolidation therapy with a continued =, 5% blasts in bone marrow and ... MPN-AP is defined by 10% to 19% blasts in the peripheral blood or bone marrow ...
Bone Marrow Neoplasms. *Bone Marrow Neoplasms: drug therapy. *Bone Neoplasms. *Bone Neoplasms: drug therapy ... RESULTS: Among 19 patients treated for NB resistant to induction therapy, 12 of 15 had complete remission (CR) of bone marrow ( ...
Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation ... Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation ... Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation ... Psaila Group - Megakaryocytes, platelets and Malignant Bone Marrow Fibrosis * Vyas Group - Normal and Leukaemic Blood Stem/ ...
Myeloproliferative Neoplasms (MPN), Polycythemia Vera (PV), Essential Thrombocytosis (ET), Primary Myelofibrosis (MF), ... Bone marrow osteoprotegerin (OPG) and interleukin-8 (IL-8) immunostaining in patients with Ph-negative myeloproliferative ... Bone marrow osteoprotegerin (OPG) and interleukin-8 (IL-8) immunostaining in patients with Ph-negative myeloproliferative ... Myeloproliferative Neoplasms (MPN), Polycythemia Vera (PV), Essential Thrombocytosis (ET), Primary Myelofibrosis (MF), ...
Myeloproliferative Neoplasms (MPN), Polycythemia Vera (PV), Essential Thrombocytosis (ET), Primary Myelofibrosis (MF), ... Bone marrow osteoprotegerin (OPG) and interleukin-8 (IL-8) immunostaining in patients with Ph-negative myeloproliferative ... Bone marrow osteoprotegerin (OPG) and interleukin-8 (IL-8) immunostaining in patients with Ph-negative myeloproliferative ... neoplasms (MPN): Clinical correlations. Diana T, Dimitrios M, Eleni-Andrianna T, Tatiana T, Theodoros I, Maria D, Aspasia K, ...
Flow cytometry to identify bone-marrow relapse in blastic plasmacytoid dendritic cell neoplasm: a case report ... Full text: Available Index: LILACS (Americas) Main subject: Recurrence / Bone Marrow / Precursor Cell Lymphoblastic Leukemia- ... Full text: Available Index: LILACS (Americas) Main subject: Recurrence / Bone Marrow / Precursor Cell Lymphoblastic Leukemia- ... Humans , Female , Middle Aged , Recurrence , Bone Marrow , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Flow Cytometry , ...
List of variants reported as likely pathogenic for connective tissue neoplasm by Bone Marrow Failure laboratory,. Queen Mary ... Acute myeloid leukemia; Dyskeratosis congenita, autosomal dominant, 2; Pulmonary fibrosis and/or bone marrow failure, telomere- ... Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1; Cutaneous malignant melanoma 9 ... Desmoid disease, hereditary; Carcinoma of colon; Familial adenomatous polyposis 1; Neoplasm of stomach; Hepatocellular ...
Bone Marrow Neoplasms / drug therapy* * Bone Marrow Neoplasms / secondary * Child * Drug Synergism ... against neuroblastoma cell lines and the subcutaneous and orthotopic xenograft model IGR-N91 derived from a primary bone marrow ...
Bone Marrow Neoplasms. Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow ... Bone Marrow Purging. Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ... Good, Bad, or Ugly: the Biological Roles of Bone Marrow Fat.. Bone marrow fat expresses mixed characteristics, which could ... Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION. ...
... covering the whole spectrum of blood and bone marrow morphology, with particular emphasis on malignant haematology. Originally ... 11 Reactive Bone Marrow Changes and Non-haemopoietic Neoplasms. Index. Reviews. "I highly recommend Morphology of Blood ... Italy are recognized experts in the morphology of blood and bone marrow. They have teamed up with Prof. Barbara Bain, from ... covering the whole spectrum of blood and bone marrow morphology, with particular emphasis on malignant haematology. Originally ...

No FAQ available that match "bone marrow neoplasms"

No images available that match "bone marrow neoplasms"